migraine - Articles and news items

migraine

Novartis to globally co-commercialise Amgen’s migraine drug

Industry news / 27 April 2017 / Niamh Marriott, Junior Editor

Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine…

Eli Lilly to aquire pain biotech CoLucid for $960 million

Industry news / 19 January 2017 / Niamh Marriott, Digital Editor

This transaction will be acting to enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch…

AMG 334 significantly reduces monthly migraine days in study

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+